These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31732945)

  • 21. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
    Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
    BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma.
    Ito M; Miyata Y; Hirano S; Kimura S; Irisuna F; Ikeda K; Kushitani K; Kishi N; Tsutani Y; Takeshima Y; Okada M
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2325-2333. PubMed ID: 31317326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer.
    Weng CF; Chen PJ; Tseng AH; Huang SH; Lee HH
    World J Surg Oncol; 2019 Aug; 17(1):148. PubMed ID: 31426797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010.
    Ito H; Date H; Shintani Y; Miyaoka E; Nakanishi R; Kadokura M; Endo S; Chida M; Yoshino I; Suzuki H;
    BMC Cancer; 2022 Aug; 22(1):875. PubMed ID: 35948946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
    Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
    Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EEF1A2 and ERN2 could potentially discriminate metastatic status of mediastinal lymph node in lung adenocarcinomas harboring EGFR 19Del/L858R mutations.
    Xia L; Wang H; Xiao H; Lan B; Liu J; Yang Z
    Thorac Cancer; 2020 Oct; 11(10):2755-2766. PubMed ID: 32881299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
    Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
    BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung.
    Kim M; Chung YS; Kim KA; Shim HS
    Lung Cancer; 2019 Nov; 137():129-135. PubMed ID: 31586770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
    Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
    J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
    Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
    BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy.
    Li R; Li Q; Lin S; Li W; Yu L; Wang L; Dong X; Yu L; Li S; Liu W; Li B
    Clin Transl Oncol; 2019 Mar; 21(3):298-303. PubMed ID: 30022385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lung adenocarcinoma with micropapillary and solid patterns: Recurrence rate and trends.
    Takeno N; Tarumi S; Abe M; Suzuki Y; Kinoshita I; Kato T
    Thorac Cancer; 2023 Oct; 14(30):2987-2992. PubMed ID: 37658844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of micropapillary component in patients with node-negative subcentimeter lung adenocarcinoma: A Chinese cohort study.
    Yao J; Zhu E; Li M; Liu J; Zhang L; Ke H; Su H; Xie H; Xu G; Zhu L; Fan J; Chen C;
    Thorac Cancer; 2020 Dec; 11(12):3566-3575. PubMed ID: 33058505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathological high malignant grade is higher risk of recurrence in pN0M0 invasive lung adenocarcinoma, even with small invasive size.
    Ito M; Miyata Y; Kushitani K; Kagimoto A; Ueda D; Tsutani Y; Takeshima Y; Okada M
    Thorac Cancer; 2021 Dec; 12(23):3141-3149. PubMed ID: 34643053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma.
    Isobe K; Kakimoto A; Mikami T; Kaburaki K; Kobayashi H; Yoshizawa T; Nakano Y; Makino T; Otsuka H; Sano G; Sugino K; Sakamoto S; Takai Y; Tochigi N; Iyoda A; Homma S
    Oncol Rep; 2018 Jul; 40(1):331-338. PubMed ID: 29767258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Associations of
    Chang JH; Lai TC; Yang PJ; Shih PC; Yang YC; Lee KL; Liu TC; Tsao TC; Yang SF; Chien MH
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific expression of MUC21 in micropapillary elements of lung adenocarcinomas - Implications for the progression of EGFR-mutated lung adenocarcinomas.
    Matsumura M; Okudela K; Nakashima Y; Mitsui H; Denda-Nagai K; Suzuki T; Arai H; Umeda S; Tateishi Y; Koike C; Kataoka T; Irimura T; Ohashi K
    PLoS One; 2019; 14(4):e0215237. PubMed ID: 30973916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function.
    Zhou J; Ben S
    Thorac Cancer; 2018 Feb; 9(2):228-233. PubMed ID: 29222872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.
    Zou J; Lv T; Zhu S; Lu Z; Shen Q; Xia L; Wu J; Song Y; Liu H
    Thorac Cancer; 2017 May; 8(3):260-270. PubMed ID: 28383802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.